Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rigel partners TGF beta inhibitors with Bristol

Executive Summary

Concurrent with its acquisition of Flexus Biosciences Inc. and related immune checkpoint assets, Bristol-Myers Squibb Co. signed a deal with Rigel Pharmaceuticals Inc. also in immuno-oncology. BMS received exclusive worldwide rights to Rigel's preclinical transforming growth factor (TGF) beta receptor kinase inhibitors.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies